{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:34:27Z","timestamp":1790080467835,"version":"4.0.1"},"reference-count":23,"publisher":"Impact Journals, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2012,12,31]]},"DOI":"10.18632\/oncotarget.692","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T21:48:09Z","timestamp":1442440089000},"page":"1557-1565","source":"Crossref","is-referenced-by-count":32,"title":["All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib"],"prefix":"10.18632","volume":"3","author":[{"given":"Oph\u00e9lie","family":"Cassuto","sequence":"first","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"},{"name":"Service d'H\u00e9matologie Clinique et de Transplantation, CHU de Nice, France"},{"name":"Centre Henri Becquerel, CLCC, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Dufies","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jacquel","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Robert","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Ginet","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Dubois","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Hamouda","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Puissant","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred\u00e9ric","family":"Luciano","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Karsenti","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Transplantation, CHU de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Transplantation, CHU de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill Patrice","family":"Cassuto","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Transplantation, CHU de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lenain","sequence":"additional","affiliation":[{"name":"Centre Henri Becquerel, CLCC, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Auberger","sequence":"additional","affiliation":[{"name":"C3M\/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France"},{"name":"Equipe Labellis\u00e9e Ligue Nationale contre le Cancer 2011-2013, Paris, France"},{"name":"Service d'H\u00e9matologie Clinique et de Transplantation, CHU de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"key":"1","first-page":"179","article-title":"The human c-abl oncogene in the Philadelphia translocation","volume":"3","author":"Grosveld","year":"1984","journal-title":"J Cell Physiol Suppl"},{"key":"2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of therapies for chronic myelogenous leukemia","volume":"17","author":"Cortes","year":"2011","journal-title":"Cancer J"},{"key":"3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.18632\/oncotarget.333","article-title":"Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy","volume":"2","author":"Turhan","year":"2011","journal-title":"Oncotarget"},{"key":"4","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.18632\/oncotarget.413","article-title":"AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications","volume":"2","author":"Platanias","year":"2011","journal-title":"Oncotarget"},{"issue":"Suppl 1","key":"5","first-page":"12","article-title":"Mechanisms of resistance to BCR-ABL kinase inhibitors","volume":"52","author":"Melo","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"6","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Pasquet","year":"2008","journal-title":"Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/leu.2009.60","article-title":"Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells","volume":"23","author":"Auberger","year":"2009","journal-title":"Leukemia"},{"key":"8","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Auberger","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"9","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","article-title":"Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC","volume":"70","author":"Auberger","year":"2010","journal-title":"Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"Pasquet","year":"2011","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.18632\/oncotarget.360","article-title":"Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells","volume":"2","author":"Auberger","year":"2011","journal-title":"Oncotarget"},{"key":"12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"Ning","year":"2009","journal-title":"Cancer Cell"},{"key":"13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhu","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"14","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","article-title":"Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant","volume":"53","author":"Das","year":"2010","journal-title":"J Med Chem"},{"key":"15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia","volume":"17","author":"Druker","year":"2011","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/sj.onc.1210034","article-title":"Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition","volume":"26","author":"Auberger","year":"2007","journal-title":"Oncogene"},{"key":"17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jmcb\/mjs010","article-title":"Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness","volume":"4","author":"Luciano","year":"2012","journal-title":"J Mol Cell Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1182\/blood-2011-05-349191","article-title":"The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"118","author":"Druker","year":"2011","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1096\/fj.03-0322","article-title":"Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage","volume":"17","author":"Auberger","year":"2003","journal-title":"FASEB J"},{"key":"20","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/leu.2010.55","article-title":"Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells","volume":"24","author":"Auberger","year":"2010","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1242\/jcs.078535","article-title":"The non-receptor tyrosine kinase Lyn controls neutrophil adhesion by recruiting the CrkL-C3G complex and activating Rap1 at the leading edge","volume":"124","author":"Wang","year":"2011","journal-title":"J Cell Sci"},{"key":"22","doi-asserted-by":"crossref","first-page":"e7889","DOI":"10.1371\/journal.pone.0007889","article-title":"Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death","volume":"4","author":"Auberger","year":"2009","journal-title":"PLoS One"},{"key":"23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.481","article-title":"BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients","volume":"3","author":"Auberger","year":"2012","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T13:40:23Z","timestamp":1594820423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["692","23238683"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.692","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}